The Landsteiner Foundation for Blood Transfusion Research (LSBR) supports clinical and experimental scientific research in the field of blood, blood-forming tissue, blood products, and blood (related) diseases, provided that the research bears a relationship to the field of transfusion or transplantation of blood cells.

Mid August 2020 the book Surviving Haemophilia, the business case of a disease written by Cees Smit was published.
The book tells the story of Cees Smit, who was born with hemophilia A almost seventy years ago. No one ever expected him to survive long into adulthood, much less old age. He survived all stages of medical innovations, with both highlights and drawbacks. Today he is a lobbyist for patients’ rights and the improvement of patients’ position in the healthcare system. The book also serves as a strong plee for European self-sufficiency in ‘red’ and ‘white’ plasma from voluntary non-remunerated donors. It is disturbing that today’s policy makers pay so little attention to the world of blood transfusion and plasma products. In a neoliberal market economy, the trade in human substances is too easily accepted.
Publication was supported by a grant from the LSBR.
ISBN: 9789463012911
In 2021 the book became available in a Dutch translation.

In November 2021 the book Els Borst, medicus in de politiek written by Nele Beyens was published by De Park Uitgeverij / Wereldbibliotheek. The presentation was on November the 50-th and publication was supported by grants from Amsterdam UMC, location AMC, ZonMW, Sanquin, de Hollandsche Maatschappij der Wetenschappen, UMC Utrecht and the LSBR.
The book is in Dutch.
ISBN: 9789028451483.

Pre-applications 2022

Submission for Pre-Applications for Scientific Research 2022 is now opened.

Granted in 2021

2103 – Dr. M. Wolkers/Dr. Branka Popović: Dissecting the interplay between RNA binding proteins and transcription factors in shaping T cell differentiation.
Budget: euro 463,783; Project duration: 3 years

2107 – Dr. J. Garaycoechea: Mapping sources of genome instability during hematopoiesis.
Budget: euro 418,390; Project duration: 4 years

2112 – Dr. M. Themeli/Dr. M. Hansen/Dr. C. Voermans: Induced pluripotent stem cells as a source of efficient and durable “off-the-shelf” CAR T cells for the treatment of cancer.
Budget: euro 492,882; Project duration: 3 years

2114 – Dr. G. Vidarsson/Dr. R. Kapur/Dr. M.D. Hazenberg: IgG-glycosylation and hexamerization as sweet spots in alloimmune responses against blood cells.
Budget: euro 480,603; Project duration: 4 years

2125 – Dr. D. Amsen: How inflammation turns regulatory T cell function on and off.
Budget: euro 452,228; Project duration: 3 years

Decisions by the Boards of the LSBR (in Dutch) can be found on the page of our Annual Report (in Dutch).